Thursday, 20 October 2016

First Europe-wide approval of the New Varroa Treatment - VARROMED


First Europe-wide approval of the New Varroa Treatment
Regarding – First Europe-wide approval of the New Varroa Treatment - VARROMED 
 Today we, BeeVital (, approach you with important news for the beekeeping world. BeeVital is a leading Bee Health company from Austria, specialized in natural products and treatments for Honey Bees.

We are very happy to inform you that after 4 years of intense work and efforts, BeeVital has received a positive opinion from the European Medicines Agency for the registration of our Varroacide VARROMED.
During its October meeting the Committee for Veterinary Medicinal Products (CVMP) has overwhelmingly voted in favor of our application to register VARROMED in all of Europe

The CVMP decision means that VARROMED will be available in all European countries, making VARROMED,
• The first EU wide registered veterinary medicine (VMP) for bees – ever!
• The first Varroa Treatment approved for “Spring Treatment, “Late summer / Autumn Treatment” and “Winter Treatment”. This means it is
• The first year-around option to combat the Varroa mite – the bees worst enemy
• The first product to have a zero day withdrawal period in combination with a year round indication.

Do not hesitate to contact us for more information. Please also find more details in the PRESS RELEASE below.

Yours sincerely,

DI Dominik N. Hohl, MBA, CEO and
Werner G. Hohl, Founder

Thursday, October 13, 2016, Salzburg/Austria.

New Varroa Treatment VARROMED – the 1st ever Bee Medicine with EU-wide approval: Ready-to-use for Spring/Autumn/Winter treatment

BeeVital introduces new Medicine against Varroosis:
For the first time the European Medicines Agency (EMA) recommended the registration of a product for bees.

VARROMED was shown to be effective in all European climate zones and will be approved for “Spring, Autumn and Winter Treatment”. This makes VARROMED the first Varroa treatment that can be used at all relevant times throughout the beekeeping year.

This approval marks a milestone in Europe-wide combating of Varroosis, still the No. 1 problem worldwide for bees and beekeepers.

VARROMED is a ready-to-use product based on a combination of natural components with the active ingredients oxalic acid and formic acid. This combination leads to increased efficacy against Varroa mites and to a better tolerance  by the bees.
The new product has been scientifically tested in the most extensive field studies with locations in Vienna, Stuttgart, Celle and Madrid representing Continental, Maritime and Mediterranean climate. Spring, Autumn and Winter tests for each climate zone were undertaken to prove the excellent efficacy of the product. The result is a product that can be used at any critical moment throughout the beekeeping year and in the Varroa life-cycle. This makes VARROMED ideal for use in integrated pest management (IPM).
"With our new product we help to effectively combated the Varroa infestation in the bee colonies and to better keep the mite levels under control," says Werner Hohl, founder of BeeVital.
VARROMED is an easy to use liquid formulation that is directly applied onto the bees simplifying Varroa treatment. For the distribution in the colony VARROMED makes use of the bees own hygienic instinct – the grooming behaviour. Due to the nature of the ingredients VARROMED does not pose any risks to honey production. In fact, this is reflected in the zero-day-withdrawal period of VARROMED approved by the EMA.

"We are looking forward to working with the beekeepers and beekeeping associations all over Europe and to continue our successful collaborations with the beekeeping community, which we have established over the past years. With our new product VARROMED we contribute significantly to the promotion of bee health. The introduction to the markets is scheduled for beginning of 2017.

BeeVital will remain committed to developing and providing natural solutions for bee health and animal welfare."
Dominik Hohl, CEO of BeeVital GmbH.